Compare NODK & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NODK | ACHV |
|---|---|---|
| Founded | 1946 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.8M | 233.2M |
| IPO Year | 2016 | 2018 |
| Metric | NODK | ACHV |
|---|---|---|
| Price | $12.83 | $3.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 19.6K | ★ 726.3K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $285,050,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $578.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.01 | $1.84 |
| 52 Week High | $14.70 | $6.03 |
| Indicator | NODK | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 38.63 | 38.39 |
| Support Level | $12.34 | $2.90 |
| Resistance Level | $13.70 | $3.39 |
| Average True Range (ATR) | 0.45 | 0.26 |
| MACD | -0.03 | -0.09 |
| Stochastic Oscillator | 5.13 | 32.74 |
NI Holdings Inc is a stockholding company. Through its subsidiaries, the company operates in the insurance industry, offering homeowners and farmowners insurance policies, crop insurance policies, home insurance policies, etc. These insurance products are distributed through a network of exclusive and independent agents across the United States. The group's reportable segments are: Private Passenger Auto, Non-Standard Auto, Home and Farm, Crop, and All Other (which mainly consists of commercial, assumed reinsurance, and its excess liability business). Maximum revenue is generated from the Home and Farm segment.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.